FY2027 Earnings Estimate for NRIX Issued By HC Wainwright

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities research analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Nurix Therapeutics in a research note issued to investors on Friday, October 16th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($2.42) per share for the year. HC Wainwright currently has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is $1.14 per share.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The business had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million.

A number of other research firms also recently issued reports on NRIX. Stifel Nicolaus set a $41.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, October 13th. UBS Group upped their target price on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday, October 15th. Truist Financial dropped their price target on shares of Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, October 13th. Finally, BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a report on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.79.

Nurix Therapeutics Trading Up 4.7%

NASDAQ NRIX opened at $26.10 on Monday. The firm has a market capitalization of $2.85 billion, a P/E ratio of 11.30 and a beta of 1.82. The business has a fifty day simple moving average of $25.09 and a 200 day simple moving average of $21.34. Nurix Therapeutics has a 12 month low of $10.15 and a 12 month high of $28.23.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NRIX. GAMMA Investing LLC increased its position in shares of Nurix Therapeutics by 95.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock valued at $30,000 after purchasing an additional 620 shares during the last quarter. Nykredit A S bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth $32,000. Integrated Wealth Concepts LLC purchased a new position in shares of Nurix Therapeutics in the 2nd quarter worth about $33,000. KBC Group NV purchased a new position in shares of Nurix Therapeutics in the 1st quarter worth about $34,000. Finally, Avalon Trust Co bought a new position in Nurix Therapeutics during the second quarter valued at about $64,000.

Insider Activity at Nurix Therapeutics

In related news, CFO Hans van Houte sold 4,761 shares of Nurix Therapeutics stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer directly owned 40,166 shares in the company, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julia P. Gregory sold 22,583 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the transaction, the director directly owned 10,750 shares in the company, valued at approximately $251,550. This represents a 67.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 45,407 shares of company stock valued at $1,083,206. 6.70% of the stock is owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.